News | April 11, 2025
US court lifts launch restrictions on Sun Pharma's autoimmune drug
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
If approved, linerixibat could address high unmet medical need of patients living with cholestatic pruritus (relentless itch) and related sleep interference
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Subscribe To Our Newsletter & Stay Updated
